Table 1.
Chronic GVHD | |||
---|---|---|---|
Characteristics | No (n = 42) | Active (n = 42) | P |
Age, median (range), y | 30 (16–61) | 30 (17–57) | 0.83 |
Gender, no (%) | 0.35 | ||
Male | 31 (73.8) | 26 (61.9) | |
Female | 11 (26.2) | 16 (38.1) | |
Primary disease, no (%)a | 0.17 | ||
ALL | 15 (35.7) | 23 (54.7) | |
AML | 24 (57.1) | 18 (42.9) | |
Others | 3 (7.2) | 1 (2.4) | |
Duration time from HSCT to sample collection, median (range), m |
8.7 (3.1–21.1) | 8.9 (3.4–19.2) | 0.98 |
Conditioning regimen, no (%)b | 0.59 | ||
Myeloablative | 35 (83.3) | 32 (76.2) | |
Intensified | 7 (16.7) | 10 (23.8) | |
HLA typing, no (%) | 0.37 | ||
Matched | 24 (57.1) | 29 (69.0) | |
Mismatched | 18 (42.9) | 13 (31.0) | |
Source of graft, no (%) | 0.12 | ||
BM + PBSC | 22 (52.4) | 14 (33.3) | |
PBSC | 20 (47.6) | 28 (66.7) | |
GVHD prophylaxis, no (%)c | <0.01 | ||
ATG based | 27 (64.3) | 13 (31.0) | |
Non-ATG based | 15 (35.7) | 29 (69.0) | |
Acute GVHD grade, no (%) | 0.46 | ||
0–I | 33 (78.6) | 29 (69.0) | |
II–IV | 9 (21.4) | 13 (31.0) | |
Immunosuppressive treatments at study inclusion, no (%)d |
<0.001 | ||
None | 18 (42.9) | 0 (0.0) | |
1 | 24 (57.1) | 10 (23.8) | |
2 | 0 (0.0) | 23 (54.8) | |
≥ 3 | 0 (0.0) | 9 (21.4) | |
Duration of immunosuppressive medication, median (range), m |
3.0 (2.0–7.0) | 9.0 (3.0–18.0) | <0.01 |
GVHD, graft-vs.-host disease; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; HSCT, hematopoietic stem cell transplantation; HLA, human leukocyte antigen; BM, bone marrow; PBSC, peripheral blood stem cell; ATG, antithymocyte globulin.
The other category included aplastic anemia, myelodysplastic syndrome, and lymphoma.
Myeloablative conditioning regimens include TBI (total body irradiation) + Cy (cyclophosphamide), Bu (busulfan)+ Cy, and Bu + Flu (fludarabine). Intensified conditioning regimens include TBI + Cy + etoposide, and Flu + cytarabine + TBI + Cy.
Non-ATG based GVHD prophylaxis include cyclosporine A (CsA), methotrexate (MTX), and mycophenolate mofetil (MMF). ATG based GVHD prophylaxis include CsA + MTX + MMF + ATG.
Immunosuppressive treatments include CsA, tacrolimus (Tac), MMF, and steroids.